In vitro Predictive Toxicity Testing
The Bioluminomics™ principle assay products for high throughput in vitro toxicity screening during early and late stage drug development.
The assays are designed for:
- Basic research toxicology and pharmacology
- Toxicology, risk and safety assessment for biopharmaceutical companies
- Environmental testing
Preferred Cell Systems™ provides assays for in vitro toxicity screening. The testing principle is based on the determination of the intracellular ATP concentration by measuring the correlated bioluminescence on 96-well plates. For validation the assay kits include standard & controls.
The Bioluminomics™ principle:
| Cell Type | Assay Name | Assay Type | Application |
|---|---|---|---|
| HEMATOPOIETIC STEM CELLS |
HALO®-Tox HT | Suspension Expansion Culture™ | High throughput hemotoxicity screening |
| HALO® PRT | Residual hemotoxicity and drug sensitivity change | ||
| MESENCHYMAL STROMA CELLS | MSCGlo™-Tox HT | Adherent cell expansion | High throughput MSC cytotoxicity screening |
| IMMUNE CELLS | ImmunoGlo™-Tox HT | Adherence or non-adherence growth-expansion | High throughput toxicity screening |
| PRIMARY STEM CELLS AND CELL LINES | STEMGlo™-Tox HT | High throughput stem cell toxicity screening | |
| STEMGlo™-PRT | Residual stem cell toxicity and drug sensitivity change | ||
| HEPATOCYTES | HepatoGlo™-Tox HT | High throughput hepatotoxicity screening |
Readout: ATP bioluminescence (96- or 384-well plates)
Kit components: Master mix, ATP standard, ATP controls, 96-well plate(s), sterile adhesive foil, manual
HALO® PRT measuring:
source: www.hemogenix.com
